COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02460224
Recruitment Status : Completed
First Posted : June 2, 2015
Last Update Posted : January 20, 2021
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This study is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LAG525 as a single agent and in combination with PDR001 to adult patients with solid tumors. The study consists of a dose escalation phase (I) to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) for LAG525 as a single agent and in combination with PDR001, and a dose expansion phase (II) which will characterize treatment of LAG525 as a single agent and in combination with PDR001 at the MTD or RP2D.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumors Drug: LAG525 Drug: PDR001 Phase 1 Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 490 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies
Actual Study Start Date : June 17, 2015
Actual Primary Completion Date : December 31, 2020
Actual Study Completion Date : December 31, 2020

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Arm A
Single agent treatment arm with LAG525
 Drug: LAG525
study drug 1
Experimental: Arm B: combination of LAG525 and PDR001
Combination treatment arm with LAG525 and PDR001
 Drug: LAG525
study drug 1

Drug: PDR001
study drug 2
Experimental: Arm C
Single agent treatment arm with LAG525 in Japanese pts
 Drug: LAG525
study drug 1


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Phase I part: Incidence of dose limiting toxicities (DLTs) [ Time Frame: 30 months ]
    A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first cycle of treatment with single agent LAG525 or within the first two cycles of treatment with the combination of LAG525 and PDR001

  2. Phase II part: Overall response Rate per RECIST V1.1 [ Time Frame: 30 months ]
    Overall Response Rate (ORR) is defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR) based on local Investigator assessment, as defined in RECIST v1.1. Estimation of the true ORR in this part of the study will be based upon the observed ORR for patients in full analysis set.


Secondary Outcome Measures :
  1. AUC [ Time Frame: 30 months ]
    Characterize the pharmacokinetic profile of single agent LAG525 given alone and in combination with PDR001

  2. Presence and/ or concentration of anti-LAG525 and anti-PDR001 antibodies [ Time Frame: 30 months ]
    Assess emergence of anti-LAG525, and anti-PDR001 antibodies following one or more intravenous (i.v.) infusions of single agent LAG525 given alone or in combination with PDR001

  3. Correlation of PD-L1, Lymphocyte activation gene-3 LAG-3 expression [ Time Frame: 30 months ]
    Assess potential predictors of efficacy of single agent LAG525 and the combination of LAG525 and PDR001

  4. Overall response Rate (ORR) [ Time Frame: 30 months ]
    Evaluate the preliminary antitumor activity per RECIST as well as per immune related Response Criteria (irRC) on single agent LAG525 given alone or in combination with PDR001

  5. Expression of IFN-γ immune-related genes by mRNA profiling [ Time Frame: 30 months ]
    Assess the pharmacodynamic effect of single agent LAG525 and the combination of LAG525 and PDR001

  6. Safety incidence of Adverse Events (AEs [ Time Frame: 30 months ]
    Characterize the safety of single agent LAG525 given alone and in combination with PDR001

  7. Tolerability measured by dose interruptions [ Time Frame: 30 months ]
    Characterize the tolerability of single agent LAG525 given alone and in combination with PDR001

  8. Progression free survival (PFS) [ Time Frame: 30 months ]
    Evaluate the preliminary antitumor activity per RECIST as well as per immune related Response Criteria (irRC) on single agent LAG525 given alone or in combination with PDR001

  9. Duration of response (DOR) [ Time Frame: 30 months ]
    Evaluate the preliminary antitumor activity per RECIST as well as per immune related Response Criteria (irRC) on single agent LAG525 given alone or in combination with PDR001

  10. Disease control rate (DCR) [ Time Frame: 30 months ]
    Evaluate the preliminary antitumor activity per RECIST as well as per immune related Response Criteria (irRC) on single agent LAG525 given alone or in combination of PDR001

  11. Safety measuresd by incidence of Serious Adverse Events (SAEs) [ Time Frame: 30 months ]
    Characterize the safety of single agent LAG525 given alone and in combination with PDR001

  12. Cmax [ Time Frame: 30 months ]
    Characterize the pharmacokinetic profile of single agent LAG525 given alone and in combination with PDR001

  13. Tmax [ Time Frame: 30 months ]
    Characterize the pharmacokinetic profile of single agent LAG525 given alone and in combination with PDR001

  14. half-life [ Time Frame: 30 months ]
    Characterize the pharmacokinetic profile of single agent LAG525 given alone and in combination with PDR001

  15. Tolerability measured by dose reductions [ Time Frame: 30 months ]
    Characterize the tolerability of single agent LAG525 given alone and in combination with PDR001


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Phase I part:

- Patients with advanced/metastatic solid tumors, with measurable or non-measurable disease as determined by RECIST version 1.1 (refer to Appendix 1), who have progressed despite standard therapy or are intolerant of standard therapy, or for whom no standard therapy exists

Phase II part:

  • Patients with advanced/metastatic solid tumors, with at least one measurable lesion as determined by RECIST version 1.1, who have had disease progression following their last prior therapy and fit into one of the following groups:
  • Group 1: NSCLC
  • Group 2: Melanoma
  • Group 3: Renal cancer
  • Group 4: Mesothelioma
  • Group 5: TNBC
  • Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1
  • Patient must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy.

Exclusion Criteria:

  • History of severe hypersensitivity reactions to study treatment ingredients or other mAbs
  • Active, known or suspected autoimmune disease
  • Active infection requiring systemic antibiotic therapy
  • HIV infection. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
  • Patients receiving chronic treatment with systemic steroid therapy, other than replacement-dose corticosteroids in the setting of adrenal insufficiency
  • Patients receiving systemic treatment with any immunosuppressive medication
  • Use of live vaccines against infectious disease within 4 weeks of initiation of study treatment
  • Systemic anti-cancer therapy within 2 weeks of the first dose of study treatment.
  • Presence of symptomatic central nervous system (CNS) metastases or CNS metastases that require local CNS-directed therapy or increasing doses of corticosteroids within the prior 2 weeks
  • History of drug-induced pneumonitis or current pneumonitis.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02460224


Locations
Layout table for location information
United States, New York
Columbia University Medical Center SC LAG X2101C
New York, New York, United States, 10032
Memorial Sloan Kettering Cancer Center SC
New York, New York, United States, 10065
United States, North Carolina
Duke Clinical Research Institute SC
Durham, North Carolina, United States, 27704
United States, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Cancer Therapy and Research Center UT Health Science Center CTRC 2
San Antonio, Texas, United States, 78229
United States, Utah
Huntsman Cancer Institute Huntsman Cancer Institute
Salt Lake City, Utah, United States, 84112
Australia, New South Wales
Novartis Investigative Site
Westmead, New South Wales, Australia, 2145
Australia, Victoria
Novartis Investigative Site
Heidelberg, Victoria, Australia, 3084
Belgium
Novartis Investigative Site
Leuven, Belgium, 3000
Canada, Alberta
Novartis Investigative Site
Edmonton, Alberta, Canada, T6G 1Z2
Canada, Ontario
Novartis Investigative Site
Toronto, Ontario, Canada, M5G 2M9
France
Novartis Investigative Site
Lyon Cedex, France, 69373
Novartis Investigative Site
Saint-Herblain Cédex, France, 44805
Germany
Novartis Investigative Site
Heidelberg, Germany, 69120
Novartis Investigative Site
Wuerzburg, Germany, 97080
Hong Kong
Novartis Investigative Site
Hong Kong, Hong Kong
Italy
Novartis Investigative Site
Milano, MI, Italy, 20133
Novartis Investigative Site
Modena, MO, Italy, 41124
Japan
Novartis Investigative Site
Fukuoka-city, Fukuoka, Japan, 811-1395
Singapore
Novartis Investigative Site
Singapore, Singapore, 119228
Novartis Investigative Site
Singapore, Singapore, 169610
Spain
Novartis Investigative Site
Barcelona, Catalunya, Spain, 08035
Novartis Investigative Site
Madrid, Spain, 28009
Taiwan
Novartis Investigative Site
Taipei, Taiwan, 10002
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT02460224    
Other Study ID Numbers: CLAG525X2101C
First Posted: June 2, 2015    Key Record Dates
Last Update Posted: January 20, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description:

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Non-small cell lung cancer
Melanoma
Renal cancer
Mesothelioma
 Triple Negative Breast
TNBC
Renal
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms